Funding TB/HIV activities:











a PEPFAR Perspective

Bruce Baird Struminger, MD, MA
Country Director
CDC Global AIDS Program, Vietnam

August 9, 2009 Bali, Indonesia




PEPFAR

(US President's Emergency Plan for AIDS Relief)

- PEPFAR I: 2004-2008, \$18.8 billion public health initiative to address the global HIV/AIDS epidemic (2-7-10 goals)
- PEPFAR II: 2009-2013, US Congressional reauthorization of \$48 billion to address the global HIV, TB, and malaria epidemics (3-12-12 goals)
 - Part of \$63 billion Global Health Initiative announced by President Obama in May, 2009
 - At least \$5 billion allocated for TB
 - Post « focus country » era
 - Partnership Frameworks central to PEPFAR II; shift from emergency response to focus on sustainability and progressive transition to local partners
- The largest international public health initiave in history
- Based on the elaboration of precise objectives and results measured against indicators with targets set by individual country teams as outlined in their annual country operational plans (COPs)
- Partnering and collaborating with all sectors of society
 - National governments, international and local NGOs, civil society,
 the private sector, UN organizations (UNAIDS, WHO, UNICEF, etc)





USG Interagency collaboration to implement PEPFAR

- Department of State
 - Office of the Global AIDS Coordinator (OGAC)
 - USAID
 - Embassies
- Department of Health and Human Services
 - CDC
 - NIH
 - HRSA
 - SAMHSA
 - FDA
- Departments of Defense, Labor, and Commerce
- Peace Corps



PEPFAR budget decision making process

USG Inter-Agency Country Team

Works together to develop the annual Country Operation Plan based on budget assigned annually by the Office of the Global AIDS Coordinator







USG HQ Inter-agency technical working groups

Technical and programmatic reviews of the country operation plans







USG Agency Principals/Deputy Principals

Review the country operation plans to ensure that congressionally mandated guidelines are followed







Office of the Global AIDS Coordinator OGAC

Final decision on financing of proposed country operation plans








Financing and oversight of activity implementation as outlined in the COPs




PEPFAR financing of TB/HIV activities 2005-2008



PEPFAR TB/HIV Technical Working Group

- Composed of HQ and field representatives from PEPFAR implementing agencies (USAID, CDC/GAP, and OGAC)
- Active collaboration with the WHO and Global Fund
- Develops priorities and technical guidelines based on international standards and recommendations
- Direct support to the implementation of high priority national level TB/HIV activities
 - Advocacy for the development of national guidelines
 - Development of national guidelines and tools for their implementation
 - Technical assistance to support the implementation of activities, including monitoring and evaluation and quality assurance





PEPFAR support to the Asia Pacific Region

- India
- China
- Cambodia
- Thailand, Laos, Indonesia, Papua New Guinea
- Vietnam
- PEPFAR support for TB in the region is primarily focused on technical assistance; Vietnam is an exception.
- PEPFAR supported TA can leverage additional funding from the GFATM and USAID.

A snapshot of PEPFAR funding for TB/HIV activities in the Asia Pacific Region:


- The case of Vietnam
 - a PEPFAR I "focus" country




Vietnam TB and HIV epidemiology*

- Population: 87 million
- General TB prevalence: 220/100,000
 - 192,000 cases (#12 on WHO list of HBCs)
- General TB incidence: 171/100,000
 - 150,000 new cases/year
 - 66,000 smear +
- General HIV prevalence: 0.3 %
 - 260,000 HIV infections
- HIV prevalence among TB patients: 8.1%
 - In HCMC it is 16%
- TB incidence among HIV+ pts initiating ART in HCMC: 27% (only 40% were smear +)
- Estimated TB/HIV co-infections: 15,500
 - *WHO Tuberculosis Control 2009 (based on 2007 data)


PEPFAR Vietnam Funding: Total



PEPFAR Vietnam Funding: TB Program Area



PEPFAR Vietnam Funding: TB Program Area as a % of Total Funding



Current focus of PEPFAR funded TB/HIV activities:

The case of Vietnam



FY 2009:

- Funding slightly decreased to \$2,554,011
- Implementing partners: GVN MOH, GVN MOD, HCMC PAC, FHI, KNCV, PATH, MDM, Harvard Medical School AIDS Initiative in Vietnam
- Activities supported included:
 - Focus on improving referral of TB patients diagnosed as HIV+ to HIV care and treatment services
 - Expansion of HIV care and treatment services (cotrim and ART) to additional TB hospitals (to ensure early OI prophylaxis and treatment of HIV)
 - Expansion of IPT from 3 to 4 provinces (12>17 sites)
 - Expansion of TB lab capacity development to 8 provinces
 - Support for TB infection control, including simple renovations and equipment purchases to improve air flow in clinic and lab spaces
 - Continue training HIV clinic staff to screen for TB
 - Concerted effort to support the implementation of WHO recommendations and priorities
 - Continued M&E capacity building

Additional USG funding for TB in the Asia Pacific Region

- In addition to PEPFAR funded TB/HIV activities, USAID Regional Development Mission Asia will be supporting a variety of TB activities with \$17.25 million in funding over three years (FY08/FY09/FY10)
- This financial support will be concentrated on the 9 high burden countries in the region: Bangladesh, Burma, Cambodia, China, India, Indonesia, Phillipines, Thailand, and Vietnam.



- Countries in the region with bilateral USAID missions can access TBCAP funds.
 - Country missions: Bangladesh, Cambodia, India, Indonesia, Philippines
 - Regional mission (Bangkok): Thailand, Cambodia, Vietnam, Myanmar, China, India, Indonesia, Philippines
- TBCAP: ~\$100m per year
 - Coalition of technical partners (ATS, CDC, FHI, IUATLD, JATA, KNCV, MSH, WHO)
 - Focus on DOTS, PPM, TB/HIV, human capacity development



Acknowledgements:

- Trinh Thanh Thuy, MD and Le Hung Thai, MD
 - CDC-GAP-Vietnam
- Sara Whitehead, MD
 - CDC Thailand (DTBE)
- Kassim SIDIBE, MD
 - CDC-GAP-Atlanta
- William Coggin, PhD
 - OGAC TB Advisor-Washington, DC

